APFED’s Hypereosinophilic Syndromes Patient Conference offered a unique opportunity to learn about treatments and research advances for hypereosinophilic syndromes (HES), and to share perspectives with the FDA and other key stakeholders about the impact of HES on patients and families, as well as how patients view current treatment approaches.
Patients and Caregivers/Family Members: If you were not able to join us for the Hypereosinophilic Syndromes (HES) Patient Conference please share your perspectives by completing the form below (make sure to click “submit”).
Comments will be summarized and shared with the FDA and other stakeholders, either verbally at the March 23 meeting, or in subsequent documentation to outline patient perspective on unmet needs in hypereosinophilic syndromes.